QIAGEN N.V. (QGEN) is likely to grow in the coming quarters, backed by its strong potential in the next- generation sequencing (NGS) platform. QIAGEN’s long-term business strategy involves forming partnerships with academic, corporate and other partners for product development, which is very promising. A strong solvency position also buoys optimism. Meanwhile, concerns loom over the impact of macroeconomic challenges on QIAGEN’s operations. Competitive disadvantages may also hurt its performance. In the pas ...